Notice of Lattice Biologics Ltd. First Quarter 2017 Financial Results Conference Call

SCOTTSDALE, AZ --(Marketwired - February 14, 2017) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (the "Company") announced today that it will release its first quarter 2017 financial results after market on Wednesday, March 1, 2017. Following this, Guy Cook, Chief Executive Officer, and Cheryl Farmer, Chief Financial Officer, will host a conference call at 6:30 a.m. PDT on Thursday, March 2, 2017 to review the results. A question and answer session will follow the corporate update.

CONFERENCE CALL DETAILS:
DATE:	Thursday, March 2, 2017
TIME:	6:30 AM Pacific Time
DIAL-IN NUMBER:	[phone]
ATTENDEE PIN:	286 6963#

Register for the online webinar for full meeting functionality:
http://www.anymeeting.com/LatticeBiologics

A recording of the call will be archived on the Company's website at:
http://www.latticebiologics.com/webinars/

Lattice Biologics Ltd.

Guy Cook, Chief Executive Officer
Telephone No: [phone]

About Lattice Biologics Ltd.:
Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.

Versatile allografts for a variety of surgical applications:

• Enhancing fusion in spine surgery
• Enhancing breast reconstruction post mastectomy for breast cancer patients
• Sports medicine indications, including ACL repair
• Promotion of bone regeneration in foot and ankle surgery
• Promotion of cranial healing following neurosurgery
• Enhancing wound repair in burn victims
• Subchondral bone defect repair in knee and other joint surgeries

The Company is currently exploring new technologies in regenerative and personalized medicine: